@article{hussain_schatman_abd-elsayed_2022, title={Knowledge Dissemination in Pain Medicine: Searching for Signal Within the Noise}, volume={15}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S372196}, abstractNote={1Department of Anesthesiology, Beth Israel Deaconess Medical Center, Harvard, Boston, MA, USA; 2Department of Anesthesiology, The Ohio State University, Wexner Medical Center, Columbus, OH, USA; 3Department of Anesthesiology, Perioperative Care, and Pain Medicine, NYU Grossman School of Medicine, New York, NY, USA; 4Department of Population Health Division of Medical Ethics, NYU Grossman School of Medicine, New York, NY, USA; 5School of Social Work, North Carolina State University, Raleigh, NC, USA; 6Department of Anesthesiology and Pain Medicine, University of Wisconsin-Madison, Madison, WI, USA}, journal={JOURNAL OF PAIN RESEARCH}, author={Hussain, Nasir and Schatman, Michael E. and Abd-Elsayed, Alaa}, year={2022}, pages={1563–1565} }
 @article{bettinger_amarquaye_fudin_schatman_2022, title={Misinterpretation of the "Overdose Crisis" Continues to Fuel Misunderstanding of the Role of Prescription Opioids}, volume={15}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S367753}, abstractNote={1Saratoga Hospital Medical Group, Saratoga Springs, NY, USA; 2HCA Florida Brandon Hospital, Brandon, FL, USA; 3President, Remitigate Therapeutics, Delmar, NY, USA; 4Department of Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, USA; 5Department of Pharmacy Practice, Western New England University College of Pharmacy, Springfield, MA, USA; 6Department of Pharmacy and Pain Management, Stratton VA Medical Center, Albany, NY, USA; 7Department of Anesthesiology, Perioperative Care, and Pain Medicine, NYU Grossman School of Medicine, New York, NY, USA; 8Department of Population Health – Division of Medical Ethics, NYU Grossman School of Medicine, New York, NY, USA; 9School of Social Work, North Carolina State University, Raleigh, NC, USA}, journal={JOURNAL OF PAIN RESEARCH}, author={Bettinger, Jeffrey J. and Amarquaye, William and Fudin, Jeffrey and Schatman, Michael E.}, year={2022}, pages={949–958} }
 @article{dias_schatman_2022, title={Pain Management Providers in the Era of COVID-19: Who is Taking Care of Those Who Provide Care?}, volume={15}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S356744}, abstractNote={Gabriela Toutin Dias,1 Michael E Schatman2– 4 1Psychology Assessment Center, Massachusetts General Hospital, Boston, MA, USA;2Department of Anesthesiology, Perioperative Care and Pain Medicine, NYU School of Medicine, New York, NY, USA;3Division of Medical Ethics, NYU School of Medicine, New York, NY, USA;4School of Social Work, North Carolina State University, Raleigh, NC, USA Correspondence: Michael E Schatman Department of Anesthesiology, Perioperative Care and Pain Medicine, NYU School of Medicine, 550 First Avenue, New York, NY, 10016, USA Tel +1 425-647-4880 Email [email protected]}, journal={JOURNAL OF PAIN RESEARCH}, author={Dias, Gabriela Toutin and Schatman, Michael E.}, year={2022}, pages={67–70} }
 @article{abd-elsayed_martens_fiala_schatman_2022, title={p Radiofrequency Ablation of the Trochanteric Branches of the Femoral Nerve for the Treatment of Greater Trochanteric Syndrome}, volume={15}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S343165}, abstractNote={Background Approximately 10–15% of the population over the age of 60 suffers from hip pain. Greater trochanteric pain syndrome (GTPS) is one of the most common diagnoses in patients with chronic hip pain, includes a number of disorders, and has a broad differential diagnosis. Conservative managements of GTPS, including pharmacologic interventions, physical therapy, chiropractic intervention, acupuncture, and more invasive techniques, such as intra-articular injections, commonly fail to provide patients with sufficient, long-term relief. While radiofrequency ablation (RFA) has been used to treat intra-articular hip pain in the past, there is little evidence for the feasibility of RFA for managing patients with GTPS. This case series builds on previous evidence that cooled radiofrequency ablation (CRF) of the trochanteric branch of the femoral nerve may offer patients with GTPS effective, safe, and lasting pain improvement. Cases A series of eight patients with GTPS underwent CRF of the nervus females to the trochanter. CRF procedures were either targeted at the left, right, or bilateral nerves. Conclusion This case series provides additional evidence for the safety and effectiveness of CRF of the nervus femoralis to the trochanter for offering long-term pain relief in patients with GTPS. All patients experienced at least two months of relief, with most patients experiencing ongoing relief from the procedure.}, journal={JOURNAL OF PAIN RESEARCH}, author={Abd-Elsayed, Alaa and Martens, Joshua M. and Fiala, Kenneth J. and Schatman, Michael E.}, year={2022}, pages={115–122} }
 @article{schatman_shapiro_2021, title={Chronic Pain Patient "Advocates" and Their Focus on Opiophilia: Barking Up the Wrong Tree?}, volume={14}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S349631}, abstractNote={1Division of Medical Ethics, NYU School of Medicine, New York, NY, USA; 2Department of Anesthesiology, Perioperative Care, and Pain Medicine, NYU School of Medicine, New York, NY, USA; 3School of Social Work, North Carolina State University, Raleigh, NC, USA; 4McLean Hospital, Division of Alcohol, Drugs, and Addiction, Harvard Medical School, Boston, MA, USA The “war on opioids” is well publicized, albeit sometimes misguided. Much has been written on how efforts to reduce the flow of prescription opioids have morphed into a war on chronic pain patients. There have been numerous editorials and articles published expressing concerns regarding the unfortunate consequences of the resulting “opiophobia” and “oligoanalgesia”, and many other key opinion leaders have and continue to express similar concerns. Efforts to counteract these tragic consequences have met with a degree of success, although much more needs to be done if chronic pain patients for whom there are frequently no other viable, accessible alternatives to opioid analgesia are to regain access to judiciously prescribed opioids. Unfortunately, advocacy for patients with pain, particularly on social media, has seemingly devolved into purely advocacy for access to opioids. We see this as problematic on a number of levels. First and foremost, opioids are not the only treatment for many types of chronic pain, and certainly not necessarily the safest and most effective. Pain management should be based on best practices guided by clinical judgement and the supporting science. Opioids and other analgesics, as well as many procedures and surgeries, generally represent purely biomedical approaches to chronic pain. Over 2 decades ago, Rollin “Mac” Gallagher astutely noted that “The history of pain medicine is replete with failures of the biomedical model”. (p. 559). Numerous others with broader understandings of pain management have subsequently echoed his sentiments. The importance of providing chronic pain patients with education in order to help them reconceptualize their pain away from flawed biomedical approaches has also been addressed in the literature. Accordingly, we posit that advocating solely for access to opioid analgesia is in fact advocating for ineffective, purely biomedical care, as opposed to coordinated interdisciplinary treatment that is likely to be far more beneficial for most patients. Second, the image of patients with chronic pain (as well as that of many of us who treat them) is less than stellar at this juncture. Radically anti-opioid forces have done their best to discredit patients with chronic pain through the use of stigmatizing and marginalizing rhetoric and hyperbole. For example, when interviewed for an article published in the Richmond Times-Dispatch in 2015, Andrew Kolodny (an addiction psychiatrist, not a pain physician) reportedly stated, “When we talk about opioid painkillers we are essentially talking about heroin pills”. More recently, Dr Keith Humphreys (an addiction psychologist, not a pain psychologist) testified to a US House of Representatives subcommittee, stating “as long as we continue putting countless Americans in 'heroin Correspondence: Michael E Schatman Division of Medical Ethics, Department of Population Health, NYU School of Medicine, 550 First Avenue, New York, NY, 10016, USA Tel +1 425-647-4880 Email Michael.Schatman@NYULangone.org}, journal={JOURNAL OF PAIN RESEARCH}, author={Schatman, Michael E. and Shapiro, Hannah}, year={2021}, pages={3627–3630} }
 @article{abd-elsayed_heyer_schatman_2021, title={Disparities in the Treatment of the LGBTQ Population in Chronic Pain Management}, volume={14}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S348525}, abstractNote={1Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 2Department of Anesthesiology, Perioperative Care and Pain Medicine, NYU School of Medicine, New York, NY, USA; 3Division of Medical Ethics, NYU School of Medicine, New York, NY, USA; 4School of Social Work, North Carolina State University, Raleigh, NC, USA It is becoming increasingly important to recognize discrepancies in the care of lesbian, gay, bisexual, transgender, or queer (LGBTQ) patients in all medical subspecialties, and in pain management there is no exception. The percentage of Americans aged 18 or older who identify as LGBTQ has risen from 4.5% in 2017 to 5.6% in 2020. One in six adults in Gen Z identify as LGBTQ.}, journal={JOURNAL OF PAIN RESEARCH}, author={Abd-Elsayed, Alaa and Heyer, Ann M. and Schatman, Michael E.}, year={2021}, pages={3623–3625} }
 @article{papa_di dato_lo bianco_gazzerro_salzano_di costanzo_tammaro_schatman_varrassi_2021, title={Intraarticular STP Radiofrequency for Painful Osteoarthritis in the Knee: A Retrospective Single Center Analysis}, volume={14}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S317569}, abstractNote={Objective Osteoarthritis (OA) is the most common cause of chronic knee pain, often a debilitating condition that can cause a significant reduction in functional capacity. Radiofrequency is a form of neuromodulation that modulates pain signal transmission and has become progressively more common as a treatment for knee pain. This retrospective study aims to evaluate the efficacy of intraarticular radiofrequency in patients with chronic knee OA pain. Materials and Methods In this retrospective study, we included 129 patients undergoing intraarticular pulsed radiofrequency using the Poisson curve for energy distribution (Sluijter-Teixeira Poisson radiofrequency) (STP) from March 2018 to November 2019. Knee osteoarthritis severity was assessed prior to the procedure using the Lequesne Index, classifying patients into six groups based on level of severity. Pain intensity was assessed through a 10-cm visual analog scale (VAS), and level of patient satisfaction was assessed through a questionnaire. Results In the sample, pain reduction as measured by VAS compared to baseline prior to the procedure was statistically significant immediately following the procedure, at 30 days and at 90 days (p<0.001); this difference was less significant at 180 days (p<0.005). Efficacy in patients with moderate to severe disability was considerably greater than in patients with very severe to extremely severe disability. 57.36% reported that they were very satisfied, 29.46% satisfied, 9.3% neither satisfied nor dissatisfied, 2.33% dissatisfied, and 1.55% very dissatisfied. Conclusion Our results suggest that STP radiofrequency may be a safe and effective procedure for knee OA, able to significantly reduce VAS scores at 1 month and 3 months compared to baseline. Based on our results, a key factor to consider when treating knee OA with STP radiofrequency is that it is more effective among patients with a lower level of disability. Due to the retrospective observational study design, prospective longitudinal investigation is required to further support the recommendation of STP radiofrequency for knee OA.}, journal={JOURNAL OF PAIN RESEARCH}, author={Papa, Alfonso and Di Dato, Maria Teresa and Lo Bianco, Giuliano and Gazzerro, Giuseppe and Salzano, Anna Maria and Di Costanzo, Emilio and Tammaro, Dario and Schatman, Michael E. and Varrassi, Giustino}, year={2021}, pages={2441–2447} }
 @article{schatman_petersen_sayed_2021, title={No Zero Sum in Opioids for Chronic Pain: Neurostimulation and the Goal of Opioid Sparing, Not Opioid Eradication}, volume={14}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S323661}, abstractNote={1Department of Diagnostic Sciences, Tufts University School of Dental Medicine, Boston, MA, USA; 2Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA; 3School of Social Work, North Carolina State University, Raleigh, NC, USA; 4Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 5Department of Anesthesiology and Pain Medicine, The University of Kansas Medical Center, Kansas City, KS, USA In 1967, Dr Norm Shealy and his colleagues reported on the first spinal cord stimulator (SCS) for dorsal stimulation. Unfortunately, the patient succumbed to undiagnosed bacterial endocarditis 6 days following the onset of stimulation. Irrespective, the first patent for spinal cord stimulation was granted in 1968. The first fully implantable SCS system was provided in 1981, with the first rechargeable system developed and released in 2004. Subsequently, the use of SCS to treat neuropathic pain has gained progressive popularity. Initially, strong evidence was rare, many systematic reviews failed to establish strong supporting evidence, and there were numerous complications associated with the large and cumbersome units that were utilized for decades. As the technology (and perhaps identification of appropriate patient candidates and technical expertise of interventionalists and surgeons) improved, the evidence-basis of SCS assessed via systematic reviews began to improve in the latter part of the first decade of this millennium. The demonstrated efficacy of neuromodulation for neuropathic pain conditions increased dramatically over the past decade as the quantity and caliber of published clinical results burgeoned. With the advent of new technologies such as highfrequency, burst SCS, and dorsal root ganglion stimulation – all of which provide advantages to the low-frequency, tonic stimulation that was provided by older units – further improvements in outcomes were reported. Not only do the newer units provide paresthesia-free or minimal-paresthesia analgesia, but they have been demonstrated through myriad systematic reviews to be safe, clinically effective, and even cost-effective in treating neuropathic pain of axial spine or radicular origin, as well as radicular symptoms, in addition to other types of neuropathic pain across different populations. While SCS has been a treatment option for chronic pain for only half a century, accounts of the use of opioids date back to at least 1550 BC, when an ancient Egyptian pharmacopoeia contained prescriptions for uses of opium. Although effective as analgesics for many types of pain, opioids’ efficacy for neuropathic pain has been determined to be extremely limited, at best. Additionally, systematic reviews point to issues of tolerability, and adverse effects including, but not limited to, constipation, cognitive dysfunction, endocrinopathy, mood disturbance, and sleep apnea. Although some studies have attempted to Correspondence: Michael E Schatman Tel +1 425-647-4880 Email Michael.Schatman@tufts.edu}, journal={JOURNAL OF PAIN RESEARCH}, author={Schatman, Michael E. and Petersen, Erika A. and Sayed, Dawood}, year={2021}, pages={1809–1812} }
 @article{scrivani_keith_kulich_dasilva_donoff_handa_holland_lerman_mccauley_reisner_et al._2021, title={Pain Management for Dental Medicine in 2021: Opioids, Coronavirus and Beyond}, volume={14}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S319373}, abstractNote={Abstract: Over the past year our attention has inevitably been on the coronavirus pandemic, the health and welfare of our families, patients, and office staffs as well as the re-opening of our dental practices. In addition, the opioid crisis continues, is very likely to worsen as a result of the pandemic and continues to be a challenge to Dentistry. National public health issues and healthcare disparities continue and have created a global concern for providing evidence-based, adequate pain management in the dental setting. We have brought together a group of national thought leaders and experts in this field who will share their insights on the current state of opioid prescribing in Dentistry and describe some of the exciting work being done in advancing pain management. The learning objectives for this conference proceedings were: Describing the implications of current public health concerns for safe and effective pain management in dental medicine. Identifying risk factors and understanding the current guidelines for the use of opioid and non-opioid medications in dental medicine. Analyzing the interprofessional collaborations necessary for effective pain management in dental medicine. Recognizing the challenges and opportunities brought about by the COVID-19 pandemic for the dental profession. Applying evidence-based strategies for managing the complex pain patient in the dental setting. Appraising new and future modalities for the assessment and management of orofacial pain.}, journal={JOURNAL OF PAIN RESEARCH}, author={Scrivani, Steven J. and Keith, David A. and Kulich, Ronald J. and DaSilva, Alexandre F. and Donoff, R. Bruce and Handa, Shruti and Holland, Nicole and Lerman, Mark A. and McCauley, Jenna L. and Reisner, Lori and et al.}, year={2021}, pages={1371–1387} }
 @article{bavarian_schatman_keith_2021, title={Persistent Pain Following Proplast-Teflon Implants of the Temporomandibular Joint: A Case Report and 35-Year Management Perspective}, volume={14}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S329123}, abstractNote={Abstract Over three decades ago, hundreds of predominantly young women with temporomandibular joint pain and other symptoms were implanted with a prosthetic device composed of Proplast-Teflon that subsequently caused considerable harm, with patients developing chronic pain, dysfunction, and disability. This perspective review presents such a patient who suffered for decades with severe pain despite extensive pharmacotherapy, injection therapy, multiple surgeries, and behavioral health interventions. The details of the origin and subsequent events regarding the use of Proplast-Teflon interpositional implants in the temporomandibular joint are described with resources from several different perspectives. The lessons learned demonstrate failures at the federal, professional, and individual level.}, journal={JOURNAL OF PAIN RESEARCH}, author={Bavarian, Roxanne and Schatman, Michael E. and Keith, David A.}, year={2021}, pages={3033–3046} }
 @article{petersen_schatman_sayed_deer_2021, title={Persistent Spinal Pain Syndrome: New Terminology for a New Era}, volume={14}, ISSN={["1178-7090"]}, DOI={10.2147/JPR.S320923}, abstractNote={1Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Department of Diagnostic Sciences, Tufts University School of Dental Medicine, Boston, MA, USA; 3Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA; 4School of Social Work, North Carolina State University, Raleigh, NC, USA; 5Department of Anesthesiology and Pain Medicine, The University of Kansas Medical Center, Kansas City, KS, USA; 6Spine and Nerve Center of the Virginias, Charleston, WV, USA Pain medicine and treatment of chronic pain have evolved, with many new treatment options developed just in the past decade. Leaders in pain medicine recognize that terminology needs to keep up with our understanding of disorders, their pathophysiologies, and their treatment. In the 1990s, the term “complex regional pain syndrome” (CRPS) emerged from the work of an expert group convened by the International Association for the Study of Pain (IASP). The goal was an improved term for the conditions previously labeled “reflex sympathetic dystrophy” and “causalgia” that was more general and not specific to a certain pathophysiology. This effort also delineated the subtypes of complex regional pain syndrome. Despite the expert recommendation, there were objections from several fronts to the terminology, and adoption of the term was slow. An analysis of publications from 2001 to 2012 identified that 79% used the new terminology, with a gradual increase over the time period. The terms “post-laminectomy syndrome” and “failed back surgery syndrome” (FBSS) were coined in the 1970s and then gained traction in the 1980s amid a discussion in the literature of approaches to treat persistent pain after spinal surgery. However, the terms are ambiguous, addressing a heterogeneous group of disorders that share the commonality of chronic pain and the experience of prior surgery after which pain either recurs or persists. In a 2015 analysis, Al-Kaisy et al noted that the term “failed back surgery syndrome” is pejorative and ought to be changed. Without doubt, the term is rife with ethical implications. Progressively, it is apparent that patients with nonspecific back and other types of chronic pain are stigmatized and marginalized. Compounding matters, it has been argued that this stigmatization and marginalization has likely been exacerbated by the ongoing COVID-19 crisis. The impact of stigmatization and marginalization of these unfortunate patients has been devastating, including the deterioration of pain sufferers’ trust in health care professionals, quality of the pain care that patients receive, perceived injustice (which has recently been empirically related to greater pain severity and increased functional impairment), and exacerbated psychological distress including increased depression and anxiety. Many patients whose pain is not substantially reduced by low back surgeries, irrespective of the reason, have few treatment options other than chronic opioid therapy. That there exists a copious body of literature demonstrating that opioid reliance exacerbates the stigmatization and marginalization of these patients is Correspondence: Michael E Schatman Tel +1 425-647-4880 Email Michael.Schatman@tufts.edu}, journal={JOURNAL OF PAIN RESEARCH}, author={Petersen, Erika A. and Schatman, Michael E. and Sayed, Dawood and Deer, Timothy}, year={2021}, pages={1627–1630} }